to IMGT/mAb-DB
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF

IMGT/mAb-DB ID 941
INN avizakimab
INN Number 11148
INN Prop. List 121 (2019)
INN Rec. List 83 (2020)
Common name BOS161721
Proprietary name
Species Humanized
IMGT receptor type IG
Format (legend)
Receptor identification IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB 11148
Specificity target name and species IL21 (interleukin 21) [Humanized]
Development Technology
Origin clone species
Origin clone name

Company Boston Pharmaceuticals (Cambridge MA USA)
Expression system CHO (Chinese Hamster Ovary) cells
Application Therapeutic
Clinical domain Immunology
Mechanism of action
Clinical indication Systemic lupus erythematosus (SLE)
Development status Phase I/II
Regulatory agency status and year

    Clinical trials
    Authority decisions
      External links
        Format legend:

        © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
        European Commission umontpellier CNRS